Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ir-Med Inc (OP:IRME)

0.0449 +0.0025 (+5.90%)
Streaming Delayed Price Updated: 3:08 PM EST, Nov 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ir-Med Inc

IR-MED Ltd. Announces Launch of First-in-Human Clinical Trial of Its DiaSafe(TM) Device for Diabetic Foot Ulcer (DFU) Assessment
DiaSafe™ technology for non-invasive DFU risk assessment and early intervention*The DFU treatment market is estimated to be approximately$10 billion globally1Rosh Pina,... 
Via Newsfile
Topics Artificial Intelligence
IR-MED's Key Clinical and Media Milestones
Rosh Pina, Israel--(Newsfile Corp. - October 27, 2025) - IR-Med Inc. (OTCQB: IRME), (the "Company" or "IR-Med"), a medical technology... 
Via Newsfile
Topics Artificial Intelligence
IR-MED Investor Update Letter - Sept-2025
Rosh Pina, Israel--(Newsfile Corp. - September 16, 2025) - IR-MED Inc. (OTCQB: IRME) ("IR-MED" or the "Company"), a developer of non-invasive artificial... 
Via Newsfile
Topics Artificial Intelligence
IR-MED Reports Positive Interim Results from U.S. Clinical Study of PressureSafe(TM) for Pressure Injury Assessment Across Diverse Skin Tones
PressureSafe™, IR-MED's lead product, demonstrated 94% sensitivity in assessing tissue at risk for pressure injuries prior to visible skin breakdownTechnology... 
Via Newsfile
Topics Artificial Intelligence
IR-MED Awarded $500,000 Grant from the Israel Innovation Authority to Advance AI-Powered DiaSafe(TM) Device for Diabetic Foot Ulcer Assessment
DiaSafe™, IR-MED's second product, is being developed to provide safe, real-time optical readings of biomarkers for assessment of diabetic foot... 
Via Newsfile
Topics Artificial Intelligence
IR-Med Announces Dr. David Dalton as Advisory Board member
From IR-Med, Inc.
Via GlobeNewswire
IR-MED Names Moshe Gerber as New CEO
From IR-MED
Via Business Wire
IR-Med Announces $3.2 Million Private Placement
From IR-Med
Via Business Wire
This Company Plans to Stop Pressure Wound casualties: Introducing IR-Med (OTCQB: IRME)
Via Get News
Topics Artificial Intelligence
Following Its Recent Annual Updates: IR-Med Announces OTCQB Up-listing: “A Significant Achievement for the Company”
From IR-Med
Via Business Wire
IR-Med to Announce 2022 Goals: Anticipated POC Results, File for FDA Clearance and up Listing to the OTCQB
From IR-Med
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.